T2 Biosystems Stock News

T2 Biosystems press release (TTOO): Q4 GAAP EPS of -$0.07 beats by $0.03.Revenue of $6.98M (-10.3% Y/Y) beats by $1.58M.Shares +5.6%.The company expects FY2022 total revenue of $28M…

Full Year 2021 Total Revenue Growth of 55%; Plans to Double Sepsis Revenue and T2Dx Instruments Full Year 2021 Total Revenue Growth of 55%; Plans to Double Sepsis Revenue and T2Dx Instruments

Full Year 2021 Total Revenue Growth of 55%; Plans to Double Sepsis Revenue and T2Dx Instruments Full Year 2021 Total Revenue Growth of 55%; Plans to Double Sepsis Revenue and T2Dx Instruments

T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q4 2021 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel In Late March Amylyx Pharma

LEXINGTON, Mass. , Feb. 16, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the execution of territory exclusive distribution agreements in Norway , Finland , and Türkiye.

T2 Biosystems (TTOO) has announced an amendment to its Term Loan Agreement with CRG Servicing.Both the interest-only period and the maturity date by one year from Dec. 31, 2022 to Dec

LEXINGTON, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the successful amendment and exte

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate

LEXINGTON, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial res

LEXINGTON, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the fourth quarter and full year 2021 after market close on Thursday, February 17, 2022. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

LEXINGTON, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial resul

LEXINGTON, Mass., Feb. 04, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to

T2 Biosystems <> said its T2SARS-CoV-2 Panel detects Omicron COVID-19 subvariants BA.1, BA.2, and BA.3.T2 Biosystems said to confirm that the T2SARS-CoV-2 Panel would detect the…

T2 Biosystems (TTOO) is +5.77% pre-market after the company reported preliminary Q4 revenue of $6.6M, including fourth quarter product revenue of $4M.Consensus revenue estimates for…